1. Home
  2. ALTI vs CAPR Comparison

ALTI vs CAPR Comparison

Compare ALTI & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AlTi Global Inc.

ALTI

AlTi Global Inc.

HOLD

Current Price

$4.67

Market Cap

394.0M

Sector

Finance

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$28.23

Market Cap

324.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALTI
CAPR
Founded
2020
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
394.0M
324.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ALTI
CAPR
Price
$4.67
$28.23
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$41.38
AVG Volume (30 Days)
160.0K
4.9M
Earning Date
11-12-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$226,717,000.00
$11,130,509.00
Revenue This Year
$19.78
N/A
Revenue Next Year
$7.00
$16,329.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.33
$4.30
52 Week High
$5.45
$40.37

Technical Indicators

Market Signals
Indicator
ALTI
CAPR
Relative Strength Index (RSI) 53.77 66.27
Support Level $4.54 $28.51
Resistance Level $4.76 $30.71
Average True Range (ATR) 0.21 1.51
MACD -0.06 -0.60
Stochastic Oscillator 19.44 50.78

Price Performance

Historical Comparison
ALTI
CAPR

About ALTI AlTi Global Inc.

AlTi Global Inc is an independent wealth and asset manager providing entrepreneurs, multi-generational families, institutions, and emerging next-generation leaders with fiduciary capabilities as well as alternative investment strategies and advisory services. The firm has business which is organized into two business segments namely: Wealth & Capital Solutions and the International Real Estate segment includes providing holistic solutions for wealth management clients through comprehensive range of wealth management services, including investment management and advisory services. International Real Estate segment includes assist investors with real estate co-investments, structuring and selecting partners with a track record with risk adjusted return characteristics.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: